<DOC>
	<DOC>NCT02510612</DOC>
	<brief_summary>Dexmedetomidine's Sedative Effect on Diabetic Patient</brief_summary>
	<brief_title>Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism</brief_title>
	<detailed_description>Dexmedetomidine is a high selective α2 agonist,its sedative and analgesia feature is acclaimed. The pathogenesis of type 2 diabetes mellitus is associated with α2 excessive adrenaline receptors expression. This study is to evaluate whether the use of dexmedetomidine is helpful to Diabetic Patient through its antisympathetic effect</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Vecuronium Bromide</mesh_term>
	<criteria>Age between 40 and 60 Selective epigastrium surgery In American Society of Anesthesiology (ASA) Physical Status&gt;3 Duration of operation &gt;3 hours Hypovolemia,sinus bradycardia,atrioventricular block,severe hepatic and renal dysfunction,severe cardiac insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Diabetic</keyword>
	<keyword>glycometabolism</keyword>
	<keyword>sedation</keyword>
</DOC>